Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 17, 2012

Primary Completion Date

March 16, 2016

Study Completion Date

August 29, 2016

Conditions
Melanoma
Interventions
DRUG

Sylatron

Sylatron - Once per week for 12 weeks, given as an injection under the skin.

DRUG

Yervoy

Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01496807 - Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma | Biotech Hunter | Biotech Hunter